Elie Abi Nader1, Cécile Lambe2, Cécile Talbotec2, Bénédicte Pigneur2, Florence Lacaille2, Hélène Garnier-Lengliné2, Laetitia-Marie Petit2, Catherine Poisson2, Amélia Rocha2, Odile Corriol3, Yves Aigrain4, Christophe Chardot4, Frank M Ruemmele5, Virginie Colomb-Jung2, Olivier Goulet5. 1. Departments of Pediatric Gastroenterology, Hepatology and Nutrition, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon abn.doc@gmail.com. 2. Departments of Pediatric Gastroenterology, Hepatology and Nutrition. 3. Pharmacy, and Paris Descartes University, Paris, France; and. 4. Pediatric Surgery and Transplantation, Necker Enfants Malades University Hospital, Certified Center for Home Parenteral Nutrition, National Reference Center for Rare Digestive Diseases in Children, APHP, Paris, France; Paris Descartes University, Paris, France; and. 5. Departments of Pediatric Gastroenterology, Hepatology and Nutrition, Paris Descartes University, Paris, France; and.
Abstract
BACKGROUND: Parenteral nutrition (PN) is the main treatment for intestinal failure. OBJECTIVE: We aimed to review the indications for home parenteral nutrition (HPN) in children and describe the outcome over a 14-y period from a single center. DESIGN: We conducted a retrospective study that included all children who were referred to our institution and discharged while receiving HPN between 1 January 2000 and 31 December 2013. The indications for HPN were divided into primary digestive diseases (PDDs) and primary nondigestive diseases (PNDDs). We compared our results to a previous study that was performed in our unit from 1980 to 2000 and included 302 patients. RESULTS: A total of 251 patients were included: 217 (86%) had a PDD. The mean ± SD age at HPN onset was 0.7 ± 0.3 y, with a mean duration of 1.9 ± 0.4 y. The indications for HPN were short bowel syndrome (SBS) (59%), PNDD (14%), congenital enteropathies (10%), chronic intestinal pseudo-obstruction syndromes (9%), inflammatory bowel diseases (5%), and other digestive diseases (3%). By 31 December 2013, 52% of children were weaned off of HPN, 9% of the PDD subgroup had intestinal transplantation, and 10% died mostly because of immune deficiency. The major complications of HPN were catheter-related bloodstream infections (CRBSIs) (1.7/1000 d of PN) and intestinal failure-associated liver disease (IFALD) (51 children; 20% of cohort). An increased rate of CRBSIs was observed compared with our previous study, but we saw a decreasing trend since 2012. No noteworthy deceleration of growth was observed in SBS children 6 mo after weaning off HPN. CONCLUSIONS: SBS was the major indication for HPN in our cohort. IFALD and CRBSIs were potentially life-threatening problems. Nevertheless, complication rates were low, and deaths resulted mostly from the underlying disease.
BACKGROUND: Parenteral nutrition (PN) is the main treatment for intestinal failure. OBJECTIVE: We aimed to review the indications for home parenteral nutrition (HPN) in children and describe the outcome over a 14-y period from a single center. DESIGN: We conducted a retrospective study that included all children who were referred to our institution and discharged while receiving HPN between 1 January 2000 and 31 December 2013. The indications for HPN were divided into primary digestive diseases (PDDs) and primary nondigestive diseases (PNDDs). We compared our results to a previous study that was performed in our unit from 1980 to 2000 and included 302 patients. RESULTS: A total of 251 patients were included: 217 (86%) had a PDD. The mean ± SD age at HPN onset was 0.7 ± 0.3 y, with a mean duration of 1.9 ± 0.4 y. The indications for HPN were short bowel syndrome (SBS) (59%), PNDD (14%), congenital enteropathies (10%), chronic intestinal pseudo-obstruction syndromes (9%), inflammatory bowel diseases (5%), and other digestive diseases (3%). By 31 December 2013, 52% of children were weaned off of HPN, 9% of the PDD subgroup had intestinal transplantation, and 10% died mostly because of immune deficiency. The major complications of HPN were catheter-related bloodstream infections (CRBSIs) (1.7/1000 d of PN) and intestinal failure-associated liver disease (IFALD) (51 children; 20% of cohort). An increased rate of CRBSIs was observed compared with our previous study, but we saw a decreasing trend since 2012. No noteworthy deceleration of growth was observed in SBS children 6 mo after weaning off HPN. CONCLUSIONS: SBS was the major indication for HPN in our cohort. IFALD and CRBSIs were potentially life-threatening problems. Nevertheless, complication rates were low, and deaths resulted mostly from the underlying disease.
Authors: Antonella Lezo; Antonella Diamanti; Evelyne M Marinier; Merit Tabbers; Anat Guz-Mark; Paolo Gandullia; Maria I Spagnuolo; Sue Protheroe; Noel Peretti; Laura Merras-Salmio; Jessie M Hulst; Sanja Kolaček; Looi C Ee; Joanna Lawrence; Jonathan Hind; Lorenzo D'Antiga; Giovanna Verlato; Ieva Pukite; Grazia Di Leo; Tim Vanuytsel; Maryana K Doitchinova-Simeonova; Lars Ellegard; Luisa Masconale; María Maíz-Jiménez; Sheldon C Cooper; Giorgia Brillanti; Elena Nardi; Anna S Sasdelli; Simon Lal; Loris Pironi Journal: Nutrients Date: 2022-04-30 Impact factor: 6.706
Authors: Helena A S Goldani; Marilia R Ceza; Liege L Godoy; Juliana M Giesta; Simone Beier; Juliana G Oliveira; Daltro L Nunes; Leticia Feldens; Iara R S Lucena; Adriano N R Taniguchi; Silvia C Hallberg; Daiane Durant; Simone Boettcher; Marcia A Schneider; Patricia P Mello; Mariana G L Riberg; Alana V Signorini; Cristina Miller; Berenice L Santos; Claudete O Silveira; Maira C M Morais; Terezinha V Laggazio; Carla C Costa; Carlos O Kieling Journal: J Pediatr Gastroenterol Nutr Date: 2022-05-17 Impact factor: 3.288
Authors: Susan Hill; Beth A Carter; Valeria Cohran; Simon Horslen; Stuart S Kaufman; Samuel A Kocoshis; David F Mercer; Russell J Merritt; Mikko P Pakarinen; Susan Protheroe; John F Thompson; Charles P B Vanderpool; Robert S Venick; Paul W Wales; Sharon E Smith; MinJung Yoon; Andrew A Grimm Journal: JPEN J Parenter Enteral Nutr Date: 2021-03-02 Impact factor: 4.016